2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1-benzenesulfonamide (DRF-4367): an orally active COX-2 inhibitor identified through pharmacophoric modulation.
| Autor: | Singh SK; Discovery Chemistry, Discovery Research-Dr. Reddy's Laboratories Ltd., Bollaram Road, Miyapur, Hyderabad 500 049, India. sunilkumarsingh@drreddys.com, Vobbalareddy S, Kalleda SR, Rajjak SA, Casturi SR, Datla SR, Mamidi RN, Mullangi R, Bhamidipati R, Ramanujam R, Akella V, Yeleswarapu KR |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Organic & biomolecular chemistry [Org Biomol Chem] 2004 Sep 07; Vol. 2 (17), pp. 2442-50. Date of Electronic Publication: 2004 Aug 11. |
| DOI: | 10.1039/B402787F |
| Abstrakt: | Analogs of 1,5-diarylpyrazoles with a novel pharmacophore at N1 were designed, synthesized and evaluated for the in-vitro cyclooxygenase (COX-1/COX-2) inhibitory activity. The variations at/around position-4 of the C-5 phenyl ring in conjunction with a CF3 and CHF2 groups at C-3 exhibited a high degree of potency and selectivity index (SI) for COX-2 inhibition. The in-vivo evaluation of these potent compounds with a few earlier ones indicated the 4-OMe-phenyl analog and the 4-NHMe-phenyl analog with a CF3, and the 4-OEt-phenyl analog with a CHF2 group at C-3 to possess superior potency than celecoxib. In addition to its impressive anti-inflammatory, antipyretic, analgesic and anti-arthritic properties, compound (DRF-4367) was found to possess an excellent pharmacokinetic profile, gastrointestinal (GI) safety in the long-term arthritis study and COX-2 potency in human whole blood assay. Thus, compound was selected as an orally active anti-inflammatory candidate for pre-clinical evaluation. (Copyright 2004 The Royal Society of Chemistry) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|